By: 28 April 2020
US FDA approves Emerphed from Nexus Pharmaceuticals

The US Food and Drug Administration has approved Emerphed, the first and only premixed ephedrine in a ready-to-use 50 mg/10 mL vial, according to its maker, Nexus Pharmaceuticals.

The ephedrine sulfate injection is an alpha- and beta-adrenergic agonist and a norepinephrine-releasing agent that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.

Emerphed will be available in a ready-to-use 10 mL vial that does not require further dilution. Each vial contains 50 mg ephedrine sulfate in 0.9% sodium chloride.

Mariam Darsot, Chief Executive Officer of Nexus Pharmaceuticals, said: “With the approval of our Emerphed Injection, Nexus Pharmaceuticals is looking to streamline the standard of care in the operating room.”

Shahid Ahmed, Chief Scientific Officer, added: “By offering a premixed, ready-to-use formulation of ephedrine, we are helping to reduce precious time spent preparing drugs in the OR, as well as reducing waste and minimising the potential for human error.”